HER2 Negative Breast Carcinoma
10
8
10
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
30%
3 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (10)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Neoadjuvant Breast Cancer Time Restricted Eating
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs